{
  "ticker": "PAR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973721",
  "id": "02973721",
  "pages": 12,
  "price_sensitive": true,
  "date": "20250729",
  "time": "0926",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m7th0d8wswlf.pdf",
  "summary": "**Summary of ASX Announcement (Quarterly Report & Appendix 4C)**  \n\n- **Phase 3 Trial Progress**:  \n  - First patients screened and nearing dosing in Australia/US.  \n  - 27 sites initiated (15 Australia, 12 US active).  \n\n- **Funding Secured**:  \n  - US$27m (A$41.2m) convertible note facility with Obsidian Global.  \n  - Initial US$7m drawn; remaining US$20m available in tranches.  \n\n- **Pipeline Expansion**:  \n  - Acquired Proteobioactives, adding oral **Pentacoxib\u2122** IP for OA (human/veterinary markets).  \n\n- **Cash Position**:  \n  - A$16.82m at 30 June 2025 (+US$7m drawn post-quarter).  \n  - Forecast Q3 cash outflow: A$10m\u201312m.  \n  - Fully funded through mid-2026 interim analysis.  \n\n- **Operational Spend**:  \n  - Quarterly R&D spend: A$6.09m (site activations, recruitment).  \n\n**Key Dates**: N/A (No material capital raising or corporate action timelines disclosed).  \n\n*Excluded*: Media/webinar links, director commentary, non-material pipeline details.",
  "usage": {
    "prompt_tokens": 6602,
    "completion_tokens": 268,
    "total_tokens": 6870,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-28T23:47:37.888834"
}